Sequence: GWTLNSAGYLLGKINLKALAALAKKILdRdRdRdRdRdRdRdRdR
| Experiment Id | EXP002390 |
|---|---|
| Paper | Transportan-derived cell-penetrating peptide delivers siRNA to inhibit replication of influenza viru |
| Peptide | T9(dR) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 200 µL IV injection; peptide amount not explicitly stated for siNP groups (complexed with 10 or 50 nmol siNP) |
| Rna Concentration | 10 nmol or 50 nmol siNP (IV, tail vein) given 6 h before PR8 challenge |
| Mixing Ratio | 4:1 (T9(dR):siRNA molar; used throughout study) |
| Formulation Format | non-covalent peptide/siRNA nanoparticles (electrostatic complex) |
| Formulation Components | T9(dR) + siNP mixed in PBS; 5% (w/v) glucose in PBS used for IV injections |
| Size Nm | 350.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c mice (female, 6-week; influenza PR8 H1N1 challenge) |
| Administration Route | intravenous (tail vein) siNP/T9(dR) complex; intranasal PR8 challenge 6 h later |
| Output Type | survival and weight recovery after lethal PR8 challenge |
| Output Value | 100% survival reported for 50 nmol siNP + T9(dR) group |
| Output Units | |
| Output Notes | After IV dosing, mice challenged intranasally with 100× MLD50 PR8. 50 nmol siNP + T9(dR) group survived with weight recovery by ~day 14; 10 nmol showed partial protection (Figure 6; text/abstract). |
| Toxicity Notes | MTT: cell viability not substantially affected at 10 µM; estimated LD50 ~85 µM in 293T; reported low cytotoxicity vs TP. |
| Curation Notes |